Jazz Pharmaceuticals announced that the FDA has granted accelerated approval of Modeyso, the first and only current treatment for recurrent H3 K27M-mutant diffuse midline glioma, an ultra-rare and aggressive brain tumor. This newly approved therapy is based on technology jointly owned by Penn, Wayne State University and Penn State University. Read more here.